Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure. / Jeppesen, Palle B.; Gabe, Simon M.; Seidner, Douglas L.; Lee, Hak Myung; Olivier, Clément.

I: Gastroenterology, Bind 154, Nr. 4, 2018, s. 874-885.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Jeppesen, PB, Gabe, SM, Seidner, DL, Lee, HM & Olivier, C 2018, 'Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure', Gastroenterology, bind 154, nr. 4, s. 874-885. https://doi.org/10.1053/j.gastro.2017.11.023

APA

Jeppesen, P. B., Gabe, S. M., Seidner, D. L., Lee, H. M., & Olivier, C. (2018). Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure. Gastroenterology, 154(4), 874-885. https://doi.org/10.1053/j.gastro.2017.11.023

Vancouver

Jeppesen PB, Gabe SM, Seidner DL, Lee HM, Olivier C. Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure. Gastroenterology. 2018;154(4):874-885. https://doi.org/10.1053/j.gastro.2017.11.023

Author

Jeppesen, Palle B. ; Gabe, Simon M. ; Seidner, Douglas L. ; Lee, Hak Myung ; Olivier, Clément. / Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure. I: Gastroenterology. 2018 ; Bind 154, Nr. 4. s. 874-885.

Bibtex

@article{3c98e1f56b8348c299f5be3a3590f6b7,
title = "Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure",
abstract = "Background & Aims: Clinical studies showed teduglutide to increase urine production and reduce need for parenteral support volume in patients with short bowel syndrome (SBS) with intestinal failure, increasing intestinal wet weight absorption and reducing diarrhea. However, the effects of teduglutide on parenteral support vary among patients. We performed a post hoc analysis of a phase III placebo-controlled study to identify characteristics of patients in whom teduglutide has the largest effects on parenteral support volume response. Methods: We collected data from 85 patients with SBS with intestinal failure, according to the European Society for Clinical Nutrition and Metabolism classification system, who received teduglutide or placebo between November 25, 2008, and January 4, 2011, at 27 sites in 10 countries. Changes in parenteral support volume were evaluated according to baseline parenteral support volume, bowel anatomy (group 1, jejunostomy/ileostomy; group 2, ≥50{\%} colon-in-continuity without stoma; and group 3, other colon anatomies), and disease features (with inflammatory bowel disease, mesenteric vascular diseases, or other conditions). Correlation analyses were conducted using simple linear regression models, with unadjusted r2 values reported. Two-sided t tests were used for comparisons between treatment groups. Results: We correlated parenteral support volume reduction with teduglutide treatment and baseline parenteral support volume (y = –0.3870x + 90.0279, r2 = 0.61; P <.0001). The effects of teduglutide on absolute parenteral support volume were significantly greater in group 1 patients (reduction of 919 ± 644 mL/d), not only compared with patients given placebo (reduction of 340 ± 436 mL/d; P =.0112) but also compared with teduglutide-treated patients in group 2 (reduction of 355 ± 306 mL/d; P =.0066). Teduglutide had an intermediate effect on patients in group 3. A minority of patients with SBS and inflammatory bowel diseases had colon-in-continuity (10.5{\%} [n = 2/19]), whereas most patients with SBS and vascular or other diseases had colon-in-continuity (84.4{\%} [n = 27/32] and 67.6{\%} [n = 23/34], respectively). Conclusions: In a post hoc analysis of data from a phase III study of the effects of teduglutide on patients with SBS, we associated reduced parenteral support volume with baseline parenteral support volume, bowel anatomy, and SBS features. These findings may inform initial parenteral support volume adjustments and management of these severely disabled patients. ClinicalTrials.gov no: NCT00798967; ClinicalTrialsRegister.eu no: 2008-006193-15.",
keywords = "GLP-2 Receptor Agonist, IBD, Parenteral Nutrition, Short-Gut Syndrome",
author = "Jeppesen, {Palle B.} and Gabe, {Simon M.} and Seidner, {Douglas L.} and Lee, {Hak Myung} and Cl{\'e}ment Olivier",
year = "2018",
doi = "10.1053/j.gastro.2017.11.023",
language = "English",
volume = "154",
pages = "874--885",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "Elsevier",
number = "4",

}

RIS

TY - JOUR

T1 - Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure

AU - Jeppesen, Palle B.

AU - Gabe, Simon M.

AU - Seidner, Douglas L.

AU - Lee, Hak Myung

AU - Olivier, Clément

PY - 2018

Y1 - 2018

N2 - Background & Aims: Clinical studies showed teduglutide to increase urine production and reduce need for parenteral support volume in patients with short bowel syndrome (SBS) with intestinal failure, increasing intestinal wet weight absorption and reducing diarrhea. However, the effects of teduglutide on parenteral support vary among patients. We performed a post hoc analysis of a phase III placebo-controlled study to identify characteristics of patients in whom teduglutide has the largest effects on parenteral support volume response. Methods: We collected data from 85 patients with SBS with intestinal failure, according to the European Society for Clinical Nutrition and Metabolism classification system, who received teduglutide or placebo between November 25, 2008, and January 4, 2011, at 27 sites in 10 countries. Changes in parenteral support volume were evaluated according to baseline parenteral support volume, bowel anatomy (group 1, jejunostomy/ileostomy; group 2, ≥50% colon-in-continuity without stoma; and group 3, other colon anatomies), and disease features (with inflammatory bowel disease, mesenteric vascular diseases, or other conditions). Correlation analyses were conducted using simple linear regression models, with unadjusted r2 values reported. Two-sided t tests were used for comparisons between treatment groups. Results: We correlated parenteral support volume reduction with teduglutide treatment and baseline parenteral support volume (y = –0.3870x + 90.0279, r2 = 0.61; P <.0001). The effects of teduglutide on absolute parenteral support volume were significantly greater in group 1 patients (reduction of 919 ± 644 mL/d), not only compared with patients given placebo (reduction of 340 ± 436 mL/d; P =.0112) but also compared with teduglutide-treated patients in group 2 (reduction of 355 ± 306 mL/d; P =.0066). Teduglutide had an intermediate effect on patients in group 3. A minority of patients with SBS and inflammatory bowel diseases had colon-in-continuity (10.5% [n = 2/19]), whereas most patients with SBS and vascular or other diseases had colon-in-continuity (84.4% [n = 27/32] and 67.6% [n = 23/34], respectively). Conclusions: In a post hoc analysis of data from a phase III study of the effects of teduglutide on patients with SBS, we associated reduced parenteral support volume with baseline parenteral support volume, bowel anatomy, and SBS features. These findings may inform initial parenteral support volume adjustments and management of these severely disabled patients. ClinicalTrials.gov no: NCT00798967; ClinicalTrialsRegister.eu no: 2008-006193-15.

AB - Background & Aims: Clinical studies showed teduglutide to increase urine production and reduce need for parenteral support volume in patients with short bowel syndrome (SBS) with intestinal failure, increasing intestinal wet weight absorption and reducing diarrhea. However, the effects of teduglutide on parenteral support vary among patients. We performed a post hoc analysis of a phase III placebo-controlled study to identify characteristics of patients in whom teduglutide has the largest effects on parenteral support volume response. Methods: We collected data from 85 patients with SBS with intestinal failure, according to the European Society for Clinical Nutrition and Metabolism classification system, who received teduglutide or placebo between November 25, 2008, and January 4, 2011, at 27 sites in 10 countries. Changes in parenteral support volume were evaluated according to baseline parenteral support volume, bowel anatomy (group 1, jejunostomy/ileostomy; group 2, ≥50% colon-in-continuity without stoma; and group 3, other colon anatomies), and disease features (with inflammatory bowel disease, mesenteric vascular diseases, or other conditions). Correlation analyses were conducted using simple linear regression models, with unadjusted r2 values reported. Two-sided t tests were used for comparisons between treatment groups. Results: We correlated parenteral support volume reduction with teduglutide treatment and baseline parenteral support volume (y = –0.3870x + 90.0279, r2 = 0.61; P <.0001). The effects of teduglutide on absolute parenteral support volume were significantly greater in group 1 patients (reduction of 919 ± 644 mL/d), not only compared with patients given placebo (reduction of 340 ± 436 mL/d; P =.0112) but also compared with teduglutide-treated patients in group 2 (reduction of 355 ± 306 mL/d; P =.0066). Teduglutide had an intermediate effect on patients in group 3. A minority of patients with SBS and inflammatory bowel diseases had colon-in-continuity (10.5% [n = 2/19]), whereas most patients with SBS and vascular or other diseases had colon-in-continuity (84.4% [n = 27/32] and 67.6% [n = 23/34], respectively). Conclusions: In a post hoc analysis of data from a phase III study of the effects of teduglutide on patients with SBS, we associated reduced parenteral support volume with baseline parenteral support volume, bowel anatomy, and SBS features. These findings may inform initial parenteral support volume adjustments and management of these severely disabled patients. ClinicalTrials.gov no: NCT00798967; ClinicalTrialsRegister.eu no: 2008-006193-15.

KW - GLP-2 Receptor Agonist

KW - IBD

KW - Parenteral Nutrition

KW - Short-Gut Syndrome

U2 - 10.1053/j.gastro.2017.11.023

DO - 10.1053/j.gastro.2017.11.023

M3 - Journal article

C2 - 29174926

AN - SCOPUS:85043237562

VL - 154

SP - 874

EP - 885

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 4

ER -

ID: 214462294